These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 3851703)

  • 1. Generation of the bioactive kallikrein-derived fragment, C3d-k, by HANE-plasma.
    Seya T; Nagasawa S; Atkinson JP
    Clin Exp Immunol; 1985 Oct; 62(1):208-16. PubMed ID: 3851703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Physiologic inactivation of fluid phase C3b: isolation and structural analysis of C3c, C3d,g (alpha 2D), and C3g.
    Davis AE; Harrison RA; Lachmann PJ
    J Immunol; 1984 Apr; 132(4):1960-6. PubMed ID: 6607952
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Generation of three different fragments of bound C3 with purified factor I or serum. II. Location of binding sites in the C3 fragments for factors B and H, complement receptors, and bovine conglutinin.
    Ross GD; Newman SL; Lambris JD; Devery-Pocius JE; Cain JA; Lachmann PJ
    J Exp Med; 1983 Aug; 158(2):334-52. PubMed ID: 6224880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suppression of T lymphocyte functions by human C3 fragments. I. Inhibition of human T cell proliferative responses by a kallikrein cleavage fragment of human iC3b.
    Meuth JL; Morgan EL; DiSipio RG; Hugli TE
    J Immunol; 1983 Jun; 130(6):2605-11. PubMed ID: 6602172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Generation of C3d,g and C3d by urokinase-treated plasma in association with fibrinolysis.
    Seya T; Nagasawa S; Matsukura M; Hasegawa H; Atkinson JP
    Complement; 1985; 2(2-3):165-74. PubMed ID: 2935360
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Limited proteolysis of complement protein C3b by regulatory enzyme C3b inactivator: isolation and characterization of a biologically active fragment, C3d,g.
    Seya T; Nagasawa S
    J Biochem; 1985 Jan; 97(1):373-82. PubMed ID: 3158646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bovine conglutinin binds to an oligosaccharide determinant presented by iC3b, but not by C3, C3b or C3c.
    Laursen SB; Thiel S; Teisner B; Holmskov U; Wang Y; Sim RB; Jensenius JC
    Immunology; 1994 Apr; 81(4):648-54. PubMed ID: 7518801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unique role of the complement receptor CR1 in the degradation of C3b associated with immune complexes.
    Medof ME; Iida K; Mold C; Nussenzweig V
    J Exp Med; 1982 Dec; 156(6):1739-54. PubMed ID: 7175439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A discontinuous factor H binding site in the third component of complement as delineated by synthetic peptides.
    Lambris JD; Avila D; Becherer JD; Müller-Eberhard HJ
    J Biol Chem; 1988 Aug; 263(24):12147-50. PubMed ID: 2969896
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cleavage of membrane bound C3bi, an intermediate of the third component of complement, to C3c and C3d-like fragments by crude leucocyte lysosomal lysates and purified leucocyte elastase.
    Carlo JR; Spitznagel JK; Studer EJ; Conrad DH; Ruddy S
    Immunology; 1981 Oct; 44(2):381-91. PubMed ID: 7028603
    [TBL] [Abstract][Full Text] [Related]  

  • 11. C3d-K, a kallikrein cleavage fragment of iC3b is a potent inhibitor of cellular proliferation.
    Thoman ML; Meuth JL; Morgan EL; Weigle WO; Hugli TE
    J Immunol; 1984 Nov; 133(5):2629-33. PubMed ID: 6332857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Breakdown of C3 after complement activation. Identification of a new fragment C3g, using monoclonal antibodies.
    Lachmann PJ; Pangburn MK; Oldroyd RG
    J Exp Med; 1982 Jul; 156(1):205-16. PubMed ID: 6177820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of interleukin 3 function by a fragment of the third component of complement.
    Fassbender B; Schmitt E; Bitter-Suermann D; Hadding U
    Eur J Immunol; 1987 May; 17(5):695-700. PubMed ID: 3495444
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A synthetic nonapeptide corresponding to the NH2-terminal sequence of C3d-K causes leukocytosis in rabbits.
    Hoeprich PD; Dahinden CA; Lachmann PJ; Davis AE; Hugli TE
    J Biol Chem; 1985 Mar; 260(5):2597-600. PubMed ID: 3871772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interactions of plasma kallikrein and C1-s with normal and dysfunctional C1(-)-inhibitor proteins from patients with hereditary angioneurotic edema: analytic gel studies.
    Donaldson VH; Wagner CJ; Tsuei B; Kindness G; Bing DH; Harrison RA; Rosen FS
    Blood; 1987 Apr; 69(4):1096-101. PubMed ID: 3493816
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Partial characterization of physiologically generated C3 components expressing C3d but not C3c epitopes.
    Siersted HC; Jensenius JC; Svehag SE; Brandslund I
    J Clin Lab Immunol; 1983 Dec; 12(4):201-8. PubMed ID: 6198522
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monoclonal antibodies against complement 3 neoantigens for detection of immune complexes and complement activation. Relationship between immune complex levels, state of C3, and numbers of receptors for C3b.
    Aguado MT; Lambris JD; Tsokos GC; Burger R; Bitter-Suermann D; Tamerius JD; Dixon FJ; Theofilopoulos AN
    J Clin Invest; 1985 Oct; 76(4):1418-26. PubMed ID: 2932466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cleavage of the complement system C3 component by HIV-1 proteinase.
    Kisselev AF; Mentele R; von der Helm K
    Biol Chem; 1997 May; 378(5):439-42. PubMed ID: 9191031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. C3d,g is present in normal human epidermal basement membrane.
    Basset-Seguin N; Dersookian M; Cehrs K; Yancey KB
    J Immunol; 1988 Aug; 141(4):1273-80. PubMed ID: 3135326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interaction of fibronectin with complement component C3.
    Hautanen A; Keski-Oja J
    Scand J Immunol; 1983 Mar; 17(3):225-30. PubMed ID: 6402811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.